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ttp://dx.doi.org/10.1016/j.ajpath.2013.02.041Cancer treatments using ionizing radiation (IR) therapy are thought to act primarily through the
induction of tumor cell damage at a molecular level. However, a new concept has recently emerged,
suggesting that the immune system is required for effective IR therapy. Our work here has identiﬁed
interferon gamma (IFN-g) as an essential cytokine for the efﬁcacy of IR therapy. Local IR (15 Gy) to mice
bearing Colon38, a colon adenocarcinoma, decreases tumor burden in wild-type animals. Interestingly, IR
therapy had no effect on tumor burden in IFNgKO mice. We further determined that intratumoral levels of
IFN-g increased 2 days following IR, which directly correlated with a decrease in tumor burden that was
not a result of direct cytotoxic effects of IFN-g on tumor cells. T cells from IR-treated tumors exhibited
a far greater capacity to lyse tumor cells in a 51Cr release assay, a process that was dependent on IFN-g.
CD8þ T cells were the predominant producers of IFN-g, as demonstrated by IFN-g intracellular staining
and studies in IFN-g reporter mice. Elimination of CD8þ T cells by antibody treatment reduced the
intratumoral levels of IFN-g by over 90%. More importantly, elimination of CD8þ T cells completely
abrogated the effects of radiation therapy. Our data suggest that IFN-g plays a pivotal role in mediating
the antitumor effects of IR therapy. (Am J Pathol 2013, 182: 2345e2354; http://dx.doi.org/10.1016/
j.ajpath.2013.02.041)Supported by NIH grant RO1CA28332 (E.M.L.).Historically, ionizing radiation (IR) therapy was thought to
control cancer predominantly by inducing tumor cell death
through DNA damage. However, a new paradigm is emer-
ging, strongly suggesting that the immune system mediates
many of the antitumor effects of radiotherapy. Our laboratory
has previously demonstrated that local radiation therapy in
a melanoma mouse model results in tumor cell death, facili-
tating the release of tumor antigen.1 Freed antigen can be
processed by antigen-presenting cells and used to stimulate
effector cells within the draining lymph node. Consequently,
these effector cells were able to trafﬁc to the tumor where they
could recognize and lyse malignant cells, thereby reducing
tumor growth. Additional reports have supported the concept
that the immune system is pivotal in determining the effec-
tiveness of radiation therapy.2e5 Lee et al3 demonstrated that
CD8þ T cells partially mediated the therapeutic effects of
radiation, whereas Apetoh et al2 identiﬁed Toll-like receptor
4epositive (TLR4þ) dendritic cells as potent immunostimu-
latory cells capable of processing and presenting antigen from
dying irradiated tumor cells. As a whole, there is increasingstigative Pathology.
.evidence of immune involvement in the anticancer effects of
radiotherapy; however, the exact mechanisms governing this
response are largely unknown and may differ from one
malignancy to another.
Irradiation of normal tissue, and now more recently
described, tumor tissue, induces an inﬂammatory state often
resulting in the secretion of cytokines into the micro-
environment.6e9 This is likely the result of danger signals
released by damaged or dying cells in response to DNA
strand breaks.8 Whereas once largely ignored, it is now
appreciated that these cytokines may impact the effectiveness
of radiotherapy, either positively or negatively, by contrib-
uting to radioresistance or radiosensitivity as well as inducing
or suppressing a radiation-mediated immune response. An
example of a cytokine with opposing effects on tumors is
interferon gamma (IFN-g). IFN-g, an inﬂammatory cytokine
that we determined was up-regulated following radiation in
a melanoma model,10 has conventionally been viewed as
Table 1 Antibodies Used in Flow Cytometry
Antibody against Clone Manufacturer
CD4 L3T4 BD Biosciences
CD8 53-6.7 eBioscience
(San Diego, CA)
CD11c HL3 BD Biosciences
CD11b M1/70 eBioscience
CD19 ID3 BD Biosciences
CD25 PC61 BD Biosciences
CD45 30-F11 BD Biosciences
CD119 GR20 BD Biosciences
NK1.1 PK136 BD Biosciences
F4/80 BM8 eBioscience
FoxP3 KIT Cat#.77-5775-40 eBioscience
GR-1 RB6-8C5 eBioscience
IFNg XMB1.2 BD Biosciences
MHC I (H-2kb) AF6-88.5 BD Biosciences
Fc Block 2.4G2 BD Biosciences
Gerber et alantagonistic to tumor growth.11 The biological functions of
this cytokine include direct cytotoxic/antiproliferative effects
on tumor cells as well as stimulation of the adaptive arm of
the immune system against tumor antigens.10 However,
recent reports have questioned the efﬁcacy of IFN-g as an
antitumor agent, instead citing situations where IFN-g
appears to promote tumor progression.11 Depending on the
dose, IFN-g was shown to promote metastases of B16 to the
lung as well as stimulate the proliferation of NIH-3T3
cells.12,13 Additionally, under certain circumstances, IFN-g
inhibited the antitumor function of NK cells and stimulated
immunosuppression through the development of T regula-
tory (Treg) and/or myeloid-derived suppressor cells along
with the production of inhibitory molecules like indoleamine
2,3-dioxygenase (IDO).14e17 Therefore, in a unique situation
such as tumor radiotherapy in which the efﬁcacy depends on
a potent immune response, we addressed whether IFN-g is
detrimental or beneﬁcial with regard to modulating the
immune system following radiotherapy.
In this report, we determined that IFN-g was not only
beneﬁcial, but was essential in mediating the antitumor
effects of radiation in a mouse colon adenocarcinoma
tumor.18 IFN-g was up-regulated in the tumor microenvi-
ronment 2 days following radiation, and CD8þ T cells were
the chief producers of this cytokine. Elimination of CD8þ T
cells, not only greatly reduced the intratumoral (i.t.) levels
of IFN-g, but also abrogated any antitumor effect of radi-
ation. Furthermore, we demonstrated that although IFN-g
had no direct effect on tumor cells in promoting tumor
control, it enhanced the cytolytic capacity of T cells,
possibly in an autocrine manner, resulting in a decrease of
tumor burden.
Materials and Methods
Mice and Cell Lines
C57BL/6J and B6.129S7-Ifngtm1Ts (IFNg/) mice were
purchased from the Jackson Laboratory (Bar Harbor, ME).
Bicistronic IFN-g reporter [Yeti (yellow-enhanced transcript
for IFN-g)] mice19 were obtained from Dr. Troy Randall
(University ofAlabama atBirmingham).Allmicewere treated
in accordance to guidelines approved by the University
Committee on Animal Resources. Colon38,18 a murine colon
adenocarcinoma, was obtained from Dr. Edward Brown and
maintained in MAT/P medium (US patent 4.816.401) sup-
plemented with 100 U/mL penicillin, 100 mg/mL strepto-
mycin, and 2% fetal calf serum. Colon38/dominant negative
receptor (DNR) clones (0.1 and 0.2) were generated by stably
transfecting parental Colon38 with a plasmid encoding an
IFN-g DNR (pcDNA.mugR) as previously described.10
Tumor Growth and Treatment
Mice were injected with 1  105 Colon38 cells i.m. into the
left thigh. Tumor size was measured using calipers and2346mean thigh diameter was calculated (square root of the
quantity W  H, where W is the width and H is the height).
Mice were restrained and received 15-Gy local irradiation
directly to the tumor-bearing leg, 7 days following tumor
challenge as previously described.1 Mice were sacriﬁced for
analysis on indicated days. To deplete CD8þ T cells, mice
were treated with 200 mg of anti-CD8 (53-6.7) diluted in
balanced salt solution (Sigma-Aldrich, St. Louis, MO) i.p.
1 day before tumor challenge and then every 4 days until
sacriﬁce. Rat IgG diluted in balanced salt solution was used
as a vehicle control.
Tumor Homogenization and IFN-g ELISA
To measure i.t. levels of IFN-g, approximately 200 mg of
tumor tissue was removed and placed in 500 mL of Lysis 11
buffer20 containing protease inhibitors (BioVision, Milpitas,
CA) and homogenized on ice for 30 to 60 seconds using
a Bio-Gen PRO200 tissue homogenizer (PRO Scientiﬁc,
Oxford, CT). Samples were centrifuged (2300  g) at 4C
for 8 minutes, and supernatant was collected and tested
either for total protein using a BCA kit (Pierce Biotech-
nology, Rockford, IL) or for IFN-g by enzyme-linked
immunosorbent assay (ELISA) (PeproTech, Rocky Hill,
NJ) according to the manufacturer’s instructions. IFN-g
concentration was normalized to total protein.
Flow Cytometric Analysis
Tumors were dissociated as previously described.21 Brieﬂy,
tumor pieces were weighed, minced, and digested for 45
minutes in collagenase D (Sigma-Aldrich). Single-cell
suspensions were counted, blocked using Fc Block, and
stained for the various antibodies listed in Table 1 for 30
minutes, and samples were analyzed using a FACSCanto
Flow Cytometer (BD Biosciences, San Jose, CA) and FlowJo
software version 9.4.11 (Tree Star, Ashland, OR) software.
All data in Table 2 are normalized to 100 mg of tumor. Forajp.amjpathol.org - The American Journal of Pathology
Table 2 Cell Number of Intratumoral Immune Subsets per 100 mg of Tumor (106)
Tumor Cells
Total
CD45þ CD8þ T cells
Total CD4þ
T cells Tregs NK cells Macrophages Monocytes
Dendritic
cells
Day 7 13  2 11  1 0.3  0.04 0.2  0.03 0.1  0.01 0.6  0.08 4.8  0.7 2.5  0.6 0.4  0.06
Day 9 UT 14  2 11  2 0.7  0.2 0.4  0.09 0.3  0.03 0.4  0.08 5.7  1 2.9  0.8 0.4  0.08
Day 9 IR 8.7  1 9  1 0.3  0.05 0.1  0.02* 0.07  0.004* 0.3  0.06 4.4  0.4 2.5  0.7 0.3  0.05
Day 11 UT 16  1 13  2 2.4  0.6 0.4  0.06 0.3  0.04 0.4  0.07 6.7  0.9 2.2  0.4 0.2  0.04
Day 11 IR 4.7  0.8* 18  4 2.7  1 0.3  0.06 0.1  0.04* 0.6  0.1 6.8  1 4.3  0.9 0.4  0.1
Cell populations are deﬁned as follows: tumor cells: CD45, forward scatterhi; CD8þ T cells: CD45þ, CD8þ; CD4þ T cells: CD45þ, CD4þ; Tregs: CD45þ, CD4þ,
FoxP3þ; NK cells: CD45þ, NK1.1þ; macrophages: CD45þ, F480hi, forward scatterhi; monocytes: CD45þ, F480intermediate, forward scatterlow; dendritic cells:
CD45þ, F480-, CD11bþ, CD11cþ. Data were generated from at least six individual tumors per group to determine the means  SEM for each subset except in
Tregs, where three individual tumors were used. Comparisons were made between the UT and IR values at either the day 9 or day 11 time points in each group
(but not across groups).
*P < 0.05 as determined by one-way analysis of variance and the Bonferroni post hoc test.
IR, irradiated; UT, unirradiated.
IFN-g Enhances the Efﬁcacy of Radiationintracellular IFN-g staining, single-cell suspensions were
prepared as described above and directly (no restimulation)
ﬁxed/permeabilized using a CytoFix/CytoPerm kit according
to the manufacturer’s instructions (BD Biosciences). Sam-
ples were then stained as described above. Fluorescence
minus one (FMO) was used as staining controls. Percentages
of immune subsets were determined by ﬁrst gating on CD45þ
cells.
Immunoblots
Protein (15 to 20 mg) from tumor homogenate was loaded
per lane and subjected to SDS-PAGE and immunoblotted as
previously described.20 Antibodies used for immunoblots
were as follows: phosphorylated signal transducer and
activator of transcription 1 (pSTAT1) (sc-7988; Santa Cruz
Biotechnology, Santa Cruz, CA), total STAT1 (sc-345;
Santa Cruz Biotechnology), interferon regulatory factor 1
(IRF1) (sc-640; Santa Cruz Biotechnology), and b-actin
(Sigma-Aldrich).
FACSort and Real-Time Quantitative RT-PCR
Tumors were dissociated into single-cell suspensions as
described above. Preparations were stained as described
above with antieCD8-PE, antieCD45-PerCP, and antie
CD3-FITC. CD45þ, CD3þ, CD8þ cells were sorted using
a FACSAria ﬂuorescence-activated cell sorter (FACS) (BD
Biosciences) and immediately lysed in Buffer RLT lysis
buffer (Qiagen, Valencia, CA). RNA was puriﬁed using an
RNeasy mini kit (Qiagen) according to the manufacturer’s
instructions and quantiﬁed using a spectrophotometer. mRNA
for Tbet, FasL, CTLA4, and Prf1 (perforin) was measured
by real-time quantitative RT-PCR as previously described20
using nested primers designed to span an intron (CTLA-4:
50-ATTCTGACTTCCTCCTTTGG-30; 50-CCTGTTGTAA-
GAGGACTTCTT-30. FasL: 50-CACCAACCAAAGCCT-
TAAAG-30; 50-ATATGTGTCTTCCCATTCC-30. GAPDH:
50-CATTGCTCTCAATGACAACT-30; 50-GGGTTTCTTA-
CTCCTTGGAG-30. Perforin: 50-AAGACCTATCAGGAC-
CAGTA-30; 50-CTGTGGAGCTGTTAAAGTTG-30. Tbet:The American Journal of Pathology - ajp.amjpathol.org50-GATCATCACTAAGCAAGGAC-30; 50-ACATCCACA-
AACATCCTGTA-30). Data were normalized to GAPDH
values and expressed as fold increase over control.
Whole-Mount Histology
Tumors were examined by whole-mount histology on day
11 as previously described.22,23
51Cr Release Cytotoxicity Assay
Tumors were dissociated as described above, and tumor-
inﬁltrating lymphocytes were magnetically separated using
beads conjugated to antieThy-1 (clone T24/40.7). Tumor-
inﬁltrating lymphocytes were assayed immediately for the
ability to lyse Colon38 target cells in a standard 6-hour 51Cr
release assay.
Statistical Analysis
Results are presented as means  SE from at least three
replicates. Data were examined for signiﬁcance using paired
Student’s t-test, or a one-way analysis of variance followed
by a Bonferroni post hoc test when appropriate.
Results
IFN-g Mediates the Antitumor Effects of Radiotherapy
Our previous data have demonstrated the necessity of an
immune response in mediating the antitumor effects of
radiotherapy in a melanoma model.10 To examine the role of
IFN-g in promoting antitumor effects, we injected C57BL/6
mice with 1  105 Colon38 cells i.m. into either wild-type
(WT) or IFNgKO mice. Tumors were either untreated or
treated locally with 15-Gy g-irradiation 7 days later, and
mean thigh diameter was monitored over time. A single high
dose of radiation was used because our previous data showed
that 15 Gy stimulated a greater antitumor immune response
when compared to a 5  3-Gy fractionated dose regimen.1
Unirradiated tumors in WT mice grew progressively until2347
Figure 1 The antitumor effects of radiation therapy are abrogated in
IFNgKO mice. A total of 1  105 Colon38 tumor cells were injected i.m. into
either WT or IFNgKOmice and treated with or without 15-Gy radiation on day 7.
Tumor growth was measured and expressed as mean thigh diameter (mm). Mice
were sacriﬁced when tumors reached 11 to 13 mm in size (nZ 6). *P< 0.001
as determined by analysis of variance and the Bonferroni post hoc test.
Figure 2 Radiotherapy increases the i.t. levels of IFN-g. A total of 1 
105 Colon38 cells were injected i.m. and treated with or without 15-Gy
radiation on day 7 of tumor growth. A: Tumor homogenate was examined
for IFN-g protein by ELISA. All data are normalized to total protein. B:
Kinetic analysis of IFN-g protein plotted as fold increase of IFN-g in irra-
diated samples over unirradiated samples over time (nZ 6). *P < 0.05 as
determined by Student t-test.
Gerber et alanimals were sacriﬁced around day 14 (Figure 1). Radiation
therapy did not have an immediate impact on controlling
growth in WT mice because tumors grew progressively for 2
days following therapy (day 9). However, after day 9,
a signiﬁcant decrease of tumor burden was seen. Most treated
tumors eventually grew, albeit at a slower rate compared to
unirradiated control tumors. Interestingly, although unirra-
diated tumors in both IFNgKO and WT mice grew similarly,
radiation treatment was ineffective in controlling tumor
growth in IFNgKO mice (Figure 1).
To examine whether IFN-g was present within the tumor
microenvironment, tumor homogenates from treated and
untreated mice were analyzed for IFN-g by ELISA. All
results were standardized to total protein. IFN-g was
signiﬁcantly induced following radiotherapy on days 9, 10,
and 11 (Figure 2A) when compared to unirradiated control.
Figure 2B represents the fold increase of IFN-g in irradiated
over unirradiated tumor samples over time and illustrates
that minimal cytokine induction is seen on day 8 (24 hours
after IR therapy). However, i.t. levels of IFN-g are increased
on day 9 and remain elevated out to day 11. This rise in the
level of IFN-g correlates with the decrease of tumor burden
following radiotherapy at the same time point (Figure 1).
These data demonstrate that i.t. levels of IFN-g are
increased following radiotherapy. More importantly, we
have identiﬁed IFN-g as an essential cytokine that appears
to mediate the antitumor effects of radiation therapy.
Intratumoral IFN-g Does Not Act Directly on Tumor
Cells to Promote Radiation-Induced Tumor Control
To assess the mechanism by which IFN-g mediates the
antitumor effects of radiotherapy, we examined whether
radiation-induced IFN-g was directly cytotoxic to tumor
cells. Parental Colon38 cells were stably transfected with an
IFN-g DNR vector, rendering these cells unresponsive to2348IFN-g as demonstrated by their inability to phosphorylate
STAT1 or induce IRF1 following 1- and 3-hour treatments of
IFN-g in vitro (Figure 3A). Additionally, Colon38/DNR
were unable to induce major histocompatibility complex
(MHC) class I following IFN-g stimulation in vitro (data not
shown). DNR expression proved stable in vivo because
subsequent ﬂow cytometry performed on dissociated ex vivo
tumor cells (as described inMaterials andMethods) analyzed
on day 13 of tumor growth showed that the DNR tumors
retained high levels of mutant CD119 (IFN-g receptor)
expression (Supplemental Figure S1A) and exhibited lower
MHC class I expression compared to ex vivo parental tumors
(Supplemental Figure S1B). We compared the growth of
Colon38 and Colon38/DNR.1 tumors treated with or without
radiation as described above. Both tumor lines grew similarly
in untreated animals (Figure 3B). More importantly, radiation
was able to control tumor growth in a similar fashion in both
parental and DNR transfected tumors. Therefore, IFN-g is
not acting directly on tumor cells to mediate the antitumor
effects of radiotherapy.
Radiation Enhances CTL in an IFN-geDependent
Manner
We next focused on whether IFN-g may modulate immune
cell function, in particular, T cells. Both unirradiated andajp.amjpathol.org - The American Journal of Pathology
Figure 3 Tumors unable to respond to IFN-g are still susceptible to
radiation treatment. Colon38 cells were stably transfected with a plasmid
encoding a DNR to IFN-g. A: IFN-g responsiveness of cells following either
1 or 3 hours of 50 ng/mL IFN-g stimulation in vitro was assessed by Western
blot for pSTAT1, total STAT1, IRF1, and loading control b-actin. Two
separate clones (0.1 and 0.2) of Colon38/DNR including parental Colon38
(Par) were tested. B: Mice were injected i.m. with either Colon38 or
Colon38/DNR.1 and treated with or without 15-Gy radiation on day 7.
Tumor growth was measured over time (n Z 6). *P < 0.05 as determined
by analysis of variance and the Bonferroni post hoc test.
IFN-g Enhances the Efﬁcacy of Radiationirradiated tumors were examined by whole-mount micros-
copy on day 11 and exhibited abundant T cells, predominantly
CD8þ, present within the tumor microenvironment (Figure 4,
A andB). Surprisingly, therewas no apparent difference in the
number of T cells within the tumors between the unirradiated
and irradiated groups as demonstrated by the whole-mount
images (Figure 4A compared to 4B). This observation was
veriﬁed using quantitative ﬂow cytometry (described below
and in Materials and Methods) (Table 2). Additionally, we
FACS-sorted CD8þ cells from both unirradiated and irradi-
ated tumors and examined four genes associated with effector
status (T-bet, Prf1, FasL, and CTLA4) by quantitative real-
time PCR. Unexpectedly, no differences were observed in
any of the four genes between the CD8þ T cells from unir-
radiated and irradiated tumors (data not shown). Therefore,
we examined whether IFN-g may enhance cytolytic T-cell
function. T cells were puriﬁed from treated versus untreated
tumors on day 11 and immediately assayed (without further
culture or stimulation) for their ability to lyse Colon38 tumorThe American Journal of Pathology - ajp.amjpathol.orgcells in a 51Cr release assay on a per tumor basis as described
in Materials and Methods. T cells from unirradiated tumor
exhibited modest lytic activity (w25% at highest effector/
target ratio); however, following radiation therapy, the i.t. T
cells had a signiﬁcantly enhanced capacity to lyse tumor cells
(Figure 4C). To determine the role of IFN-g in this response,
the experiment was repeated using T cells isolated from
tumors growing in IFNgKO mice. T cells from unirradiated
tumors grown in IFNgKOmice exhibited little to no cytolytic
activity against Colon38. More importantly, radiotherapy did
not signiﬁcantly enhance this response. Furthermore, the
cytolytic activity of T cells from irradiated tumors in IFNgKO
mice was below the lytic capacity of T cells from both unir-
radiated and irradiated WT samples (Figure 4C). Therefore,
IFN-g, generated as a result of radiotherapy, enhances the
ability of T cells to lyse tumor cells.
CD8þ T Cells Are the Predominant Producers of
Intratumoral IFN-g
To determine which cell type(s) were responsible for
producing i.t. IFN-g, we ﬁrst identiﬁed the immune subsets
that were present within the tumor. Tumors grown for 7, 9,
or 11 days and untreated or treated with 15-Gy radiation on
day 7 were dissociated into single-cell suspensions, stained
for immune cell markers, and analyzed using multicolor
ﬂow cytometry as described inMaterials and Methods. Data
are presented as the number of cells standardized to tumor
weight in Table 2. We identiﬁed T cells, natural killer cells,
monocytes, macrophages, and dendritic cells within the
tumor microenvironment. We primarily compared differ-
ences in cell number within a particular immune subset
between the unirradiated and irradiated tumors at either day
9 or day 11. Surprisingly, the only changes were observed in
the T-cell populations as cell numbers decreased in the
irradiated tumors when compared to unirradiated tumors at
day 9. This observation is most likely a result of the
radiosensitivity of T cells. Otherwise, no signiﬁcant changes
in cell density were observed in any other immune subset,
including total CD45þ cells at either time point. Interest-
ingly, an increase of CD8þ T cells from day 9 to day 11 was
noted in both the treated and untreated groups, suggesting
that Colon38 promotes the inﬁltration of potentially tumor
reactive T cells.
We next distinguished IFN-geproducing immune cells
within the tumor using two complementary methods. First,
we used bicistronic IFN-g reporter mice (Yeti) in which
transcription of the IFNG gene also results in enhanced
yellow ﬂuorescent protein (eYFP) reporter expression.
Therefore, immune cells producing IFN-g mRNA will also
be YFPþ. Colon38 tumors were grown in either WT or Yeti
mice and treated with or without radiation as described
above. Tumors were dissociated and single-cell suspensions
were analyzed for YFP expression by ﬂow cytometry. A
YFPþ population that was not present in WT mice was
clearly evident in all tumor samples (Figure 5A). Further2349
Figure 4 T cells exhibit enhanced cytotoxicity following radiation therapy. Mice were injected i.m. with 1  105 Colon38 cells and treated with or without
15-Gy radiation on day 7. A and B: Tumors were removed on day 11 and examined by whole-mount histology for anti-CD31 to label blood vessels (red), anti-
CD8 (green), and anti-CD4 (blue) T cells. C: Thy1þ tumor-inﬁltrating lymphocytes were isolated from individual day 11 tumors (as described above) from either
WT or IFNgKO mice and assayed for speciﬁc lysis against 51Cr-labeled Colon38 targets. Data were generated by determining the percent speciﬁc lysis from six
individual tumors (tumor-inﬁltrating lymphocytes were not pooled) at each effector/target (E:T) ratio as described in Materials and Methods. Means  SEM
were reported (nZ 6). *P < 0.05 versus WT 0 Gy as determined by analysis of variance and the Bonferroni post hoc test; yP < 0.05 versus IFNgKO 15 Gy as
determined by analysis of variance and the Bonferroni post hoc test.
Gerber et alsubset analysis revealed that most YFPþ cells (ie, positive
for IFN-g mRNA) on day 9 were CD8þ T cells and NK
cells (Figure 5B). By day 11, about 70% of YFPþ cells were
CD8þ T cells. No differences were observed between irra-
diated and unirradiated tumor samples with regard to YFPþ
immune subsets.
Yeti mice report for IFN-g transcripts but not necessarily
those actively producing the cytokine.24 Therefore, to
examine IFN-g protein production, we used intracellular
IFN-g staining of i.t. immune subsets from WT mice as
described in Materials and Methods. IFN-gþ cells were
detected primarily in the CD45þ gated cells (Figure 5C). On
further characterization by ﬂow cytometry, IFN-gþ cells were
determined to be predominantly CD8þ T cells (Figure 5D).
The number of IFN-geproducing CD8þ T cells increased in
untreated tumors from day 7 to day 11. More importantly,
irradiation enhanced the number of IFN-gþ CD8þ T cells on
both day 9 and day 11 (2 and 4 days following radiation
therapy, respectively). Therefore, results from both the Yeti
mice and intracellular IFN-g staining concurrently identiﬁed
CD8þ T cells as the chief producers of i.t. IFN-g.CD8þ T-Cell Depletion Abrogates the Antitumor Effects
of Radiation
On the basis of the previous data, we hypothesized that
depletion of CD8þ T cells should result in decreased levels of
i.t. IFN-g. Therefore, we depleted CD8þ T cells with i.p.
injections of 200 mg of anti-CD8 starting 1 day before tumor
inoculation and every 4 days thereafter. Rat IgG was used as
a control. Anti-CD8 treatment routinely resulted in a knock-
down of approximately 90% CD8þ T cells in both the tumor
microenvironment and spleen (data not shown). Mice were
challenged with tumor and irradiated as described above.
Indeed, CD8þ T-cell depletion resulted in a substantial2350decrease in i.t. levels of IFN-g at both day 9 and day 11,
conﬁrming that CD8þ T cells are the predominant producers
of i.t. IFN-g (Figure 6A). We next examined tumor growth
kinetics with and without radiation between anti-CD8etrea-
ted and rat IgGetreated mice. Tumor growth was similar in
unirradiated tumors between the two groups. However, the
antitumor effects of radiation were completely lost in mice
that were depleted of CD8þ T cells, and therefore had low
levels of i.t. IFN-g (Figure 6B). These data identify IFN-ge
producing CD8þ T cells as an essential cell type required to
mediate the antitumor effects of radiotherapy.
Discussion
A new and exciting concept has emerged demonstrating that
the immune system plays a pivotal role in mediating the
antitumor effects of radiation therapy. Previous reports have
highlighted the contribution of dendritic cells in the presen-
tation of radiation-induced tumor antigen to the importance
of CD8þ T cells in eliciting an antitumor response following
radiotherapy.2e4,10 Our report makes a signiﬁcant contribu-
tion to understanding the mechanism of how the conse-
quential immune response following radiotherapy mediates
tumor control. In particular, we demonstrated that the Th1
cytokine, IFN-g, which was predominantly produced by i.t.
CD8þ T cells, was essential to elicit the antitumor effects of
radiation. This is particularly interesting because recent
reports suggest that IFN-g may be detrimental to tumor
control.11 Our studies differed from these reports in that we
examined the role of IFN-g in eliciting tumor control in
response to radiation therapy within a different tumor model.
In other words, our data clearly show that, in the context of
radiotherapy, the presence of i.t. IFN-g in Colon38 tumors is
beneﬁcial and promotes effective antitumor cytotoxic T cells
that are functionally active.ajp.amjpathol.org - The American Journal of Pathology
Figure 5 CD8þ T cells are the predominant
producers of i.t. IFN-g. WT and IFN-g reporter mice
(Yeti) were injected with 1  105 Colon38 cells
i.m. and treated with or without 15 Gy on day 7.
Tumors were removed at various time points,
dissociated into a single-cell suspension, and
examined for YFP expression by ﬂow cytometry.
A: Representative dot plots from either WT or Yetiþ
mice analyzed for YFPþ cells. B: YFPþ cells were
gated and immune subsets were determined by
multicolor ﬂow cytometry (n Z 4). Intracellular
staining for IFN-g was performed on single-cell
suspensions from WT mice injected with Colon38
(as described above). C: Representative dot plots
of IFN-g stained and control are provided. FMO,
ﬂuorescence minus one. D: IFN-gþ cells were
gated and immune cell subsets were determined by
multicolor ﬂow cytometry. All data were normal-
ized to tumor burden as described in Materials
and Methods (n Z 6). DC, dendritic cells; Mac,
macrophages; Mono, monocytes; SSC, side scatter;
Tg, transgenic.
IFN-g Enhances the Efﬁcacy of RadiationWe examined IFN-g production by i.t. immune cells using
both transgenic Yeti mice and intracellular staining for
protein. An attribute of transgenic Yeti mice is that they report
for IFN-g mRNA through YFP expression; however, this
does not necessarily mean that IFN-g protein is being
secreted. Mayer et al24 determined that YFPþ T cells (thus
cells making IFN-g mRNA) required an additional stimulus
such as antigen, anti-CD3, or phorbol 12-myristate 13-acetate
(PMA)/ionomycin to induce IFN-g protein secretion. In other
words, Yeti mice, through YFP expression, report for cells
that have the potential to secrete IFN-g. This important
concept can be applied to our study and is illustrated in
Figure 4B where the majority of day 11 i.t. CD8þ T cells
(70%) are YFPþ and therefore have the potential to secrete
IFN-g protein. Interestingly, intracellular staining conﬁrmed
that only 8% of CD8þT cells actually stain positive for IFN-g
protein (data not shown). We were surprised to observe that
YFP expression does not change in response to radiation even
though we detect an increase of IFN-g proteineproducingThe American Journal of Pathology - ajp.amjpathol.orgCD8þT cells from irradiated tumors. These data suggest that
radiation, or the indirect effects of radiation therapy, may
provide an additional stimulus/signal that allows cells with
the potential to secrete IFN-g (YFPþ) to actually produce
and release this protein. It is well established that radio-
therapy results in tissue damage and the subsequent
production of danger signals similar to pathogen-associated
molecular patterns or damage-associated molecular pat-
terns.8 These danger signals have the potential to induce
a proinﬂammatory tumor microenvironment through the
production of cytokines such as tumor necrosis factor
a (TNF-a), IL-1, and IFN-g.8 Also, danger signals have
been shown to directly alter immune cells. In particular,
speciﬁc signals such as uric acid, reactive oxygen species,
and heat-shock proteins can stimulate the maturation of
dendritic cells.8,25,26 Therefore, it is possible that similar
danger signals may be acting on CD8þ T cells to stimulate
the production of IFN-g and secretion into the tumor
microenvironment.2351
Figure 6 CD8þ T-cell depletion abrogates the antitumor effects of
radiation. Mice were treated with 200 mg of anti-CD8 or rat IgG antibodies
i.p. 1 day before tumor challenge and every 4 days after. Mice were chal-
lenged with 1  105 Colon38 cells i.m. and treated with or without 15 Gy
radiation 7 days later. A: Tumor homogenate was assayed for IFN-g by
ELISA and normalized to total protein. B: Tumor growth was monitored and
presented as mean thigh diameter (mm) (nZ 4). *P < 0.05 as determined
by analysis of variance and the Bonferroni post hoc test.
Gerber et alOur data identify CD8þ T cells as essential in mediating
the antitumor effects of radiation. These cells are not only
responsible for generating the increase of i.t. IFN-g
following radiation, but are likely the main effector cell type
capable of destroying tumor cells via cytolytic activity.
Interestingly, the numbers of i.t. CD8þ T cells were not
signiﬁcantly increased in irradiated tumors and, based on
four genes measuring effector status (eg, T-bet, Prf1, FasL,
and CTLA-4), FACS-sorted CD8þ T cells from irradiated
tumors were genetically similar to CD8þ T cells isolated
from unirradiated tumors as assessed by real-time PCR (data
not shown). Therefore, do differences exist between CD8þ
T cells from either untreated or irradiated tumors? Our data
suggest that T cells from irradiated tumors exhibit high
cytolytic activity against tumor targets immediately after
removal without additional culture or stimulation. This
implies that the cells are functionally active within the
irradiated tumor microenvironment. Importantly, this func-
tional advantage afforded to T cells from irradiated tumors
is dependent on IFN-g. We propose that i.t. CD8þ T cells
are stimulated by radiation-induced danger signals (see2352above) within the tumor microenvironment, which promote
the production of IFN-g protein by these same cells. The
IFN-g then acts back on the T cells in an autocrine fashion,
enhancing the cytolytic capacity of these cells. In essence,
the CD8þ T cells are modifying a potentially inhospitable
tumor microenvironment, through the release of IFN-g, to
one that is more conducive to cytolytic function.
The tumor microenvironment is likely to elicit profound
changes, both stimulatory and inhibitory, on the cytolytic
capacity of effector T cells. Therefore, in the 51Cr release
assay, we made an effort to preserve these effects by puri-
fying T cells using anti-Thy1.1, which will isolate both
CD8þ T cells along with CD4þ T cells, some of which
could be regulatory cells that may function to suppress CTL
function. However, our data in Table 2 demonstrate that
although we could detect the presence of FoxP3þ, CD4þ
Tregs in both the unirradiated and irradiated tumors at each
time point, the number of Tregs is decreased as a result of
radiation at day 9 (possibly due to the inherent radiosensi-
tive nature of lymphocytes), and remains down in irradiated
tumors at day 11 when compared to unirradiated controls.
More importantly, the CD8 to Treg ratio at day 11 is 8:1 in
unirradiated tumors and further increases to 20:1 in irradi-
ated samples. Therefore, our data suggest that radiotherapy
may modify (or alleviate) immunosuppressive component(s)
(in this example, Tregs) within the Colon38 tumor micro-
environment, thereby promoting CTL lytic function. Addi-
tional studies would need to be performed to address this
speciﬁc question; however, regardless of the mechanism, the
data presented here highlight IFN-g as the main factor in
promoting the antitumor effects of radiotherapy.
IFN-g has been shown to elicit antiproliferative or cytotoxic
effects directly on tumor cells. Moreover, the proliferative
capacity of Colon38 is greatly diminished in a dose-dependent
fashion when these cells are incubated with IFN-g in vitro
(data not shown). However, our DNRdata argue against IFN-g
acting directly on Colon38 in an antiproliferative capacity,
because tumor growth was not altered in either unirradiated or
irradiated DNR-expressing tumors when compared to parental
Colon38 (Figure 3B). This, however, should not detract from
the importance of the potential direct effects of IFN-g in other
models.Wehavepreviously shown that i.t. IFN-gwas required
to up-regulateMHC class I molecules on tumor cells following
radiation in a B16 tumormodel.10 This increase ofMHCclass I
likely plays an important role in providing tumor antigen
targets to effector CD8þ T cells, thereby facilitating immune
recognition.This is in contrast to our currentmodel inwhichwe
demonstrated that IFN-g does not act directly on tumor cells to
promote tumor control, rather its effectsmaybedirected toward
enhancing cytotoxic cells. Interestingly, the ex vivo Colon38/
DNR tumor cells (unresponsive to IFN-g) did express lower
levels of MHC class I when compared to parental tumors
following radiation.However, the expression ofMHCclass I is
inherently abundant on this cell line, and further increases of
this molecule appear to have little effect on the ability of
radiation to control tumor growth. Overall, these observationsajp.amjpathol.org - The American Journal of Pathology
IFN-g Enhances the Efﬁcacy of Radiationhighlight important differences in the mode of action of IFN-g
following radiotherapy between tumor models.
The tumor microenvironment contains a variety of cell
types, including immune, endothelial, ﬁbroblasts, and other
stromal cells, as well as malignant cells.27e29 In aggressive
malignancies, complex interactions between each cell type
may promote a tumorigenic microenvironment resulting in
tumor progression.27 However, certain factors can be intro-
duced intratumorally that could skew an otherwise tumori-
genicmicroenvironment to an immunogenic one. In our study,
radiation-induced IFN-g is an essential factor that skews the
response toward tumor destruction, thereby reducing tumor
burden. This factor was speciﬁcally induced within the tumor
microenvironment and not detectable [as assayed by Luminex
(Millipore, Billerica,MA) andELISA] systemicallywithin the
serum of these mice (data not shown). Furthermore, our data
highlight the complex nature of i.t. IFN-g within the tumor
microenvironment as this cytokine was necessary to stimulate
T cells to destroy tumor cells, but was not required to act
directly on tumor cells to promote tumor control. Other cell
types that contain abundant IFN-g receptors are presentwithin
the tumor stroma and could also be targets for this cytokine.30
In particular, IFN-g can act directly on endothelial cells to
induce cell senescence.31 Additionally, our previous work has
demonstrated that IFN-g up-regulates the adhesion molecule
vascular cell adhesion molecule 1 (VCAM-1) on tumor
endothelium10 and promotes vessel normalization,22 conse-
quences that may promote antitumor activity by facilitating
immune cell inﬁltration.32,33 Similarly, Lu et al34 demon-
strated that stromal ﬁbroblasts are abundant in tumors and
enhance tumor growth by stimulating angiogenesis. Interest-
ingly, IFN-g acted directly on ﬁbroblasts to down-regulate the
production of the angiogenic molecule VEGF-A, resulting in
angiostasis and tumor control.34
Although 15-Gy radiation treatment resulted in signiﬁcant
tumor control in our model, many of these tumors eventually
grew (Figure 1). Therefore, there is considerable room for
improvement. Our data clearly warrant further investigation
into treatment options that increase the levels of i.t. IFN-g
during radiation treatment. Delivery of high doses of cyto-
kines has been shown to elicit serious side effects when
administered systemically.35,36 Therefore, an effective, yet
safe, treatment would involve the delivery of this cytokine
directly to the tumor microenvironment. Certain technologies
such as cytokine-conjugated microspheres or fusion protein
technologymay be a possible means of targeting IFN-g to the
tumor.37,38 We speculate that the efﬁcacy of radiotherapy can
be enhanced by increasing the i.t. levels of IFN-g at the time
of, or shortly after, radiation treatment. Current studies are
examining the therapeutic potential of combining radio-
therapy with tumor-targeted IFN-g delivery in the Colon38
tumor as well as other murine tumors to ensure that the
effectiveness of the treatment is generalizable. Additional
testing will obviously be necessary, but this innovative option
has the potential to redeﬁne how radiation oncologists treat
malignancies in the clinic.The American Journal of Pathology - ajp.amjpathol.orgAcknowledgments
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